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Hemolytic uremic syndrome (HUS) is an unrare and severe thrombotic microangiopathy (TMA) caused by several pathogenetic
mechanisms among which Shiga toxin-producing Escherichia coli infections and complement dysregulation are the most common.
However, very rarely and particularly in neonates and infants, disorders of cobalamin metabolism (CblC) can present with or be
complicated byTMA.Hereinwe describe a case of atypicalHUS (aHUS) related toCblC diseasewhich first presented in a previously
healthy boy at age of 13.6 years.The clinical picture was initially dominated by nephrotic range proteinuria and severe hypertension
followed by renal failure. The specific treatment with high dose of hydroxycobalamin rapidly obtained the remission of TMA and
the complete recovery of renal function. We conclude that plasma homocysteine and methionine determinations together with
urine organic acid analysis should be included in the diagnostic work-up of any patient with TMA and/or nephrotic syndrome
regardless of age.
1. Introduction
Atypical hemolytic uremic syndrome (aHUS) is a life-threat-
ening disease characterised by thrombotic microangiopathy
(TMA) that is mainly due to Shiga toxin-producing Escher-
ichia coli infections and uncontrolled complement activation,
although it may rarely be due to other causes, such as dis-
orders of intracellular cobalamin (cbl) metabolism [1]. Meth-
ylmalonic aciduria and homocystinuria, cobalamin C type
(cblC) (OMIM 277400) is likely the most common of
such disorders and is caused by biallelic mutations in the
MMACHC gene (Lerner-Ellis et al. 2006). cblC-related TMA
has been almost mainly reported in neonates and infants [2–
8], but we have recently encountered a case that developed it
at the very unusual age of 13.6 years. Its clinical presentation
was dominated by symptoms of nephrotic syndrome and
hypertension that initially responded to eculizumab treat-
ment.
2. Case Presentation
ACaucasian son of unrelated parents was referred to our cen-
tre because of severe hypertension, nephrotic range protein-
uria, microhematuria, acute kidney injury, and signs of TMA.
His family history was unremarkable for kidney diseases and
his own previous medical history was uneventful until the
age of 8 years, when he experienced an episode of generalised
seizure in apyrexia that was not followed by any relevant event
and did not require any specific treatment.
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One month before the acute episode, the boy suffered
from severe headache and recurrent emesis associated with
a weight loss (from 47 to 43 kg) for which he was admitted to
another hospital. Severe arterial hypertension was detected
(150/110mmHg) and laboratory tests revealed nephrotic
range proteinuria (5 gr/day), associated with signs of kidney
injury: serum creatinine 1.3mg/dL, microscopic hematuria
together with mild thrombocytopenia (121,000/mm3) and
hemolytic anemia (hemoglobin 10.2 g/dL, lactic dehydroge-
nase (LDH) 894U/L, and undetectable haptoglobin). Renal
ultrasonography revealed enlarged, hyperechogenic kidneys
with reduced corticomedullary differentiation, and echocar-
diography showed left ventricular hypertrophy and a slightly
enlarged aortic bulb. During the subsequent 3 weeks pro-
teinuria increased further and renal function deteriorated
until the patient was referred to our centre. Twenty-one
days after the onset, laboratory tests at arrival were as
follows: hemoglobin: 9.6 gr/dL; platelet count: 115.000/mm3;
plasma albumin: 3.2 gr/dL; serum creatinine: 2.7 gr/dL; LDH:
484 IU/L; haptoglobin: undetectable; cholesterol 234mg/dL;
urinary protein/urinary creatinine: 5.1mg/mg.
Given the clinical picture of TMA, functional and genetic
tests for complement dysregulation were requested, and
eculizumab treatment was immediately started (900mg fol-
lowed by a second dose after seven days).
Despite efficient complement inhibition (AP
50
: 1%) and
a normalised platelet count (180,000/mm3), the hemolysis
persisted (haptoglobin < 20mg/dL) and kidney function
continued to decline reaching a peak serum creatinine level
of 7.2mg/dL. For these reasons and for the normal level of
complement C3 (93mg/dL), laboratory tests were extended
to rule out less frequent inherited causes of TMA. Hyper-
homocysteinemia (364mMol/L, normal range < 15.4) and
hypomethioninemia (8 uMol/L, normal range 15–20 uMol/L)
and increased urinary excretion of methylmalonic acid
(20mMol/mol, normal range < 2mMol/mol) were detected.
Since these metabolic alterations strongly suggested a cblC
disease, the specific treatment with intravenous hydrox-
ycobalamin (5mg/day), betaine (4 g/day), and folic acid
(5mg/day) was started on the fourteenth day. The first
evidence of a response was observed as early as 4 days after
starting the specific treatment with a clear-cut reduction
in the urinary protein/urinary creatinine ratio from 6.4 to
2.6mg/mg (Figure 1). In the meantime, complement dysreg-
ulation was ruled out by molecular analysis of the relevant
genes (CFH, CFH-related, CFI, CFB, MCP, C3) and by the
normal titre of anti-CFH antibodies. HIV, antinuclear, and
anticardiolipin antibodies and ADAMTS13 were also nor-
mal. Molecular analysis of the MMACHC gene defini-
tively confirmed the diagnosis of cblC by identifying the
known causative c.271dupA (p.Arg91Lysfs∗14) and c.388T>C
(p.Tyr130His) mutations. The p.Tyr130His has been pre-
viously described in compound heterozygous state with
c.481C>T (p.Arg161∗) mutation in a patient with onset of
disease at 17 years. Since p.Tyr130 maps in the conserved
cobalamin binding motif (122-HXXGX
126–154GG156), the
p.Tyr130His mutation may affect clb binding or protein
structural integrity and it could be associated with a late onset
phenotype.
Renal function gradually normalised during the follow-
ing six weeks, as also the other TMA laboratory parameters,
including proteinuria (Figure 1).Thirty-five days after admis-
sion, andwhile improving, the patient presented two episodes
of generalised seizure, which were attributed to posterior
reversible encephalopathy syndrome on the basis ofmagnetic
resonance imaging.
The patient is currently well, and his hypertension only
requires two drugs (atenolol and ramipril) and he is under-
going a maintenance treatment with oral hydroxycobalamin
(1mg once daily), betaine (4 g once daily), and folic acid (5mg
once daily).
3. Discussion
Both Shiga toxin-related and atypical HUS are unrare causes
of acute kidney injury in children, but cblC disorder is
responsible for fewer than 1% of TMA cases and is charac-
terised by presentation very early in life (usually at an age of
<1 year).
Our case underlines the importance of including homo-
cysteine in the initial diagnostic work-up of all nephrotic
patients beyond the typical age of idiopathic nephrotic
syndrome of infancy (<6 years) as well as all cases of aHUS
to screen for intracellular cobalaminmetabolism disorders as
these disorders are not limited to infancy.
Although most cases of aHUS are accompanied by
various degrees of proteinuria due to endothelial damage at
glomerular level, the development of overt nephrotic syn-
drome at the time of presentation is not common and may
be misleading. However, it can be useful to mention that the
loss of urinary proteins is not the onlymechanism responsible
for reduced albumin concentration in this setting: the disease
is systemic (all of the microvasculature can be damaged);
therefore widespread endothelial protein leakage takes place.
Although the pathogenetic mechanism of the endothelial
damage in cblC-related TMA is very different from that of
aHUS associated with complement dysregulation, a certain
degree of complement involvement has been hypothesised
also in other forms of TMA. In this regard, the partial but
unequivocable response to eculizumab seems to provide indi-
rect evidence that complement is involved in the mechanism
of damage.
In conclusion, we strongly recommend including plasma
homocysteine determination in the diagnostic work-up of
any patient with nephrotic syndrome and/or with TMA in
order to ensure timely diagnosis and effective treatment.
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Figure 1: Laboratory relevant to TMA activity. (a) Hematological parameters: LDH (UI/L); Hb (g/dL); platelets (103/mmc); (b) renal
parameters: serum creatinine (mg/dL); uPr/Cr (mg/mg); (c) homocysteine levels (mmol/L).
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